Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer - PubMed (original) (raw)
Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
W H West et al. N Engl J Med. 1987.
Abstract
Adoptive immunotherapy involving bolus-dose recombinant interleukin-2 (rIL-2) has been reported to induce tumor regression in some patients with cancer, but has been associated with severe fluid retention and cardiopulmonary stress. In an effort to preserve the efficacy but reduce the toxicity of this treatment, we used escalating doses of rIL-2 as a constant infusion rather than as a bolus dose. Forty-eight patients with advanced cancer received rIL-2 as a 24-hour infusion in five-day cycles separated by five-day periods of rest and leukapheresis. Eight patients were removed from the study before receiving cells activated in vitro. In the 40 who could be evaluated for their response, there were 13 partial responses (32.5 percent) and 2 minor responses. Partial responses were observed in Hodgkin's disease (one of one), non-Hodgkin's lymphoma (one of one), lung cancer (one of five), ovarian cancer (one of one), parotid cancer (one of two), renal cancer (three of six), and melanoma (five of ten). Responses were associated with a good performance status, a base-line lymphocyte count above 1400 per cubic millimeter, and an rIL-2-induced lymphocyte count of at least 6000. Optimal lymphocytosis required a priming dose of rIL-2 of 3 X 10(6) U per square meter of body-surface area per day, and 15 of 28 patients receiving this priming dose responded to treatment. A weight gain of more than 10 percent of total body weight (five patients) and dyspnea at rest (six patients) were unusual events restricted to patients with poorer pretreatment performance. We conclude that the administration of rIL-2 as a constant infusion may preserve the antineoplastic activity of adoptive immunotherapy while increasing the safety and comfort of patients.
Similar articles
- Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF. Stewart JA, et al. Cancer Res. 1990 Oct 1;50(19):6302-10. Cancer Res. 1990. PMID: 2205379 Clinical Trial. - A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. Rosenberg SA, et al. N Engl J Med. 1987 Apr 9;316(15):889-97. doi: 10.1056/NEJM198704093161501. N Engl J Med. 1987. PMID: 3493432 - Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Rosenberg SA, et al. N Engl J Med. 1985 Dec 5;313(23):1485-92. doi: 10.1056/NEJM198512053132327. N Engl J Med. 1985. PMID: 3903508 Clinical Trial. - Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
Rosenberg SA, Lotze MT. Rosenberg SA, et al. Annu Rev Immunol. 1986;4:681-709. doi: 10.1146/annurev.iy.04.040186.003341. Annu Rev Immunol. 1986. PMID: 3518753 Review. No abstract available. - The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2.
Rosenberg SA. Rosenberg SA. Semin Oncol. 1986 Jun;13(2):200-6. Semin Oncol. 1986. PMID: 3520827 Review. No abstract available.
Cited by
- Innovative optical imaging strategies for monitoring immunotherapy in the tumor microenvironments.
Um-E-Kalsoom, Wang S, Qu J, Liu L. Um-E-Kalsoom, et al. Cancer Med. 2024 Oct;13(19):e70155. doi: 10.1002/cam4.70155. Cancer Med. 2024. PMID: 39387259 Free PMC article. Review. - Biodistribution and plasma survival in mice of anti-melanoma monoclonal antibody cross-linked to OKT3.
Winkler MA, Price JO, Foglesong PD, West WH. Winkler MA, et al. Cancer Immunol Immunother. 1990;31(5):278-84. doi: 10.1007/BF01740935. Cancer Immunol Immunother. 1990. PMID: 2142894 Free PMC article. - Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
Sone S, Kunishige E, Fawzy F, Yanagawa H, Nii A, Maeda K, Atagi S, Heike Y, Nishioka Y, Mizuno K, et al. Sone S, et al. Jpn J Cancer Res. 1991 Jun;82(6):716-23. doi: 10.1111/j.1349-7006.1991.tb01908.x. Jpn J Cancer Res. 1991. PMID: 1649813 Free PMC article. - Lymphokine activated killer cells.
Lindemann A, Herrmann F, Oster W, Mertelsmann R. Lindemann A, et al. Blut. 1989 Oct;59(4):375-84. doi: 10.1007/BF00321208. Blut. 1989. PMID: 2676022 Review. - Interleukin-2-dependent long-term cultures of low-density lymphocytes allow the proliferation of lymphokine-activated killer cells with natural killer, Ti gamma/delta or TNK phenotype.
Testa U, Care A, Montesoro E, Fossati C, Giannella G, Masciulli R, Fagioli M, Bulgarini D, Habetswallner D, Isacchi G, et al. Testa U, et al. Cancer Immunol Immunother. 1990;31(1):11-8. doi: 10.1007/BF01742490. Cancer Immunol Immunother. 1990. PMID: 2306752 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources